Literature DB >> 2404582

Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.

R K Jain1.   

Abstract

The efficacy in cancer treatment of monoclonal antibodies or other macromolecules bound to radionuclides, chemotherapeutic agents, toxins, enzymes, growth factors, or effector antibodies has been limited by their inability to reach their target in vivo in adequate quantities. Heterogeneity of tumor-associated antigen expression alone has failed to explain the nonuniform uptake of antibodies. As a result, only in recent years have the peculiarities of tumor physiology been recognized as determinants of antibody distribution. Three physiological barriers responsible for the poor localization of macromolecules in tumors have been identified: (a) heterogeneous blood supply; (b) elevated interstitial pressure; and (c) large transport distances in the interstitium. The first barrier limits the delivery of blood-borne molecules to well-perfused regions of a tumor; the second barrier reduces extravasation of fluid and macromolecules in the high interstitial pressure regions and also leads to an experimentally verifiable, radially outward convection in the tumor periphery which opposes the inward diffusion; and the third barrier increases the time required for slowly moving macromolecules to reach distal regions of a tumor. Binding of antibody to an antigen further lowers the effective diffusion rate of the antibody by reducing the amount of mobile antibody. Due to micro- and macroscopic heterogeneities in tumors, the relative magnitude of each of these barriers would vary from one location to another and from one day to the next in the same tumor and from one tumor to another. If the genetically engineered macromolecules, e.g., lymphokines, and other new modalities, e.g., killer lymphocytes, as well as low molecular weight cytotoxic agents, are to fulfill their clinical promise, methods must be developed to overcome these physiological barriers. Some of these methods are discussed, and situations wherein these barriers may not be a problem are pointed out.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2404582

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  163 in total

1.  Liposome-mediated therapy of intracranial brain tumors in a rat model.

Authors:  U S Sharma; A Sharma; R I Chau; R M Straubinger
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

2.  Interstitial fluid pressure correlates with intravoxel incoherent motion imaging metrics in a mouse mammary carcinoma model.

Authors:  Sungheon Kim; Lindsey Decarlo; Gene Y Cho; Jens H Jensen; Daniel K Sodickson; Linda Moy; Silvia Formenti; Robert J Schneider; Judith D Goldberg; Eric E Sigmund
Journal:  NMR Biomed       Date:  2011-11-09       Impact factor: 4.044

Review 3.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

4.  Preclinical evaluation of Mab CC188 for ovarian cancer imaging.

Authors:  M Xu; M P Rettig; G Sudlow; B Wang; W J Akers; D Cao; D G Mutch; J F DiPersio; S Achilefu
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

5.  Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors.

Authors:  Shutao Wang; In Soo Shin; Hilary Hancock; Beom-su Jang; Hyung-sub Kim; Sang Myung Lee; Vesna Zderic; Victor Frenkel; Ira Pastan; Chang H Paik; Matthew R Dreher
Journal:  J Control Release       Date:  2012-06-23       Impact factor: 9.776

Review 6.  Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.

Authors:  Ankit I Mehta; Adam M Brufsky; John H Sampson
Journal:  Cancer Treat Rev       Date:  2012-06-22       Impact factor: 12.111

Review 7.  Ligand-targeted delivery of therapeutic siRNA.

Authors:  Yutaka Ikeda; Kazunari Taira
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

8.  Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model.

Authors:  I H Pastan; G E Archer; R E McLendon; H S Friedman; H E Fuchs; Q C Wang; L H Pai; J Herndon; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

9.  Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice.

Authors:  Biana Godin; Ciro Chiappini; Srimeenakshi Srinivasan; Jenolyn F Alexander; Kenji Yokoi; Mauro Ferrari; Paolo Decuzzi; Xuewu Liu
Journal:  Adv Funct Mater       Date:  2012-10-23       Impact factor: 18.808

Review 10.  Silicon micro- and nanofabrication for medicine.

Authors:  Daniel Fine; Alessandro Grattoni; Randy Goodall; Shyam S Bansal; Ciro Chiappini; Sharath Hosali; Anne L van de Ven; Srimeenkashi Srinivasan; Xuewu Liu; Biana Godin; Louis Brousseau; Iman K Yazdi; Joseph Fernandez-Moure; Ennio Tasciotti; Hung-Jen Wu; Ye Hu; Steve Klemm; Mauro Ferrari
Journal:  Adv Healthc Mater       Date:  2013-04-15       Impact factor: 9.933

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.